1. Amadori- 162.0528 CML-58.0055 CEL-72.0211 MGH1-54.0106 H- 1.00783 O- 15.9949

2. PLGS identified AGE modified Peptides In HSA associated with CICs from Clinical plasma (Annotated MS/MS spectra)

3. A.Unmodified peptide B.Modified peptide C.Highlighted modified residue with “b-ions” or “y ions” encompassing the modified site. The lines (blue line for “b-ion and red line for y-ion) show the mass shift (∆M) corresponding to the type of AGE modification. Depiction of AGE modified MS/MS spectra

4. CON

5. A7 Sequence: 24-34 RDAHKSEVAHR CML (5) A. B. C. ∆M ∆M (b5) = 57.988 Da +57.988 Da (CML)

6. 224-236 CASLQKFGERAFK Carbamidomethyl C (1), CEL (6) Sequence: 224-236 CASLQKFGERAFK Carbamidomethyl C (1), CEL (6) A. B. C. +72.013 Da (CEL) ∆M ∆M (b7) = 72.013 Da

7. Sequence: 453-463 NLGKVGSKCCK AMADORI (8), Carbamidomethyl C (9), Carbamidomethyl C (10) ∆M ∆M (y4) = 162.041 Da +162.041 Da (AMADORI)

8. IGT

9. +162.239 Da (AMADORI) Sequence: 206-219 LDELRDEGKASSAK AMADORI (5) A. B. C. ∆M ∆M (y11) = 162.239 Da

10. Sequence: 250-264 AEFAEVSKLVTDLTK CML (8) +57.993 Da (CML) A. B. C. ∆M1 (b8) = 57.993 Da ∆M +57.993 Da (CML)

11. + 72.671 Da (CEL) + 162.242 Da (AMADORI) Sequence: 453-463 NLGKVGSKCCK CEL (4), AMADORI (8), Carbamidomethyl C (9), Carbamidomethyl C (10) A. B. C. ∆M1 ∆M1 (y8) = 72.671 Da ∆M2 ∆M2 (y4) = 162.242 Da

12. NDD

13. Sequence: 224-236 CASLQKFGERAFK Carbamidomethyl C (1), CEL (6) A. B. C. + 71.612 Da (CEL) ∆M ∆M (y10) = 71.612 Da

14. 243-257 LSQRFPKAEFAEVSK MGH1 (4) ∆M ∆M (b5) = 54.021 Da +54.021 Da (MGH1)

15. Sequence: 250-264 AEFAEVSKLVTDLTK CML (8) +58.016 Da (CML) ∆M ∆M (b8) = 58.016 Da A. B. C.

16. Sequence: 348-361 DVFLGMFLYEYARR AMADORI (13) +162.007 Da (AMADORI) ∆M ∆M (y2) = 162.007 Da A. B. C.

17. Sequence: 549-558 KQTALVELVK AMADORI (1) + 161.952 Da (AMADORI) ∆M ∆M (b1) = 161.952 Da A. B. C.

18. DM

19. Sequence: 24-34 RDAHKSEVAHR AMADORI (1), AMADORI (5) +162.038 Da (AMADORI) ∆M1 ∆M1 (b2) = 162.038 Da ∆M2 ∆M2 (b5) = 162.070 Da A. B. C. +162.070 Da (AMADORI)

20. + 58.479 Da (CML) Sequence: 215-223 ASSAKQRLK CML (5) ∆M ∆M (y5) = 58.479 Da A. B. C.

21. +71.698 Da (CEL) Sequence: 224-236 CASLQKFGERAFK Carbamidomethyl C (1), CEL (6) A. B. C. ∆M ∆M (b7) = 71.698 Da

22. +57.998 Da (CML) Sequence: 250-264 AEFAEVSKLVTDLTK CML (8) ∆M ∆M (b8) = 57.998 Da A. B. C.

23. DM-MIC

24. F7 +57.806 Da (CML) 24-34 RDAHKSEVAHR CML (5) ∆M ∆M (y7) = 57.806 Da A. B. C.

25. Sequence: 199-210 AACLLPKLDELR Carbamidomethyl C (3), AMADORI (7) +162.032 Da (AMADORI) ∆M ∆M (b7) = 162.032 Da A. B. C.

26. Sequence: 250-264 AEFAEVSKLVTDLTK CML (8) ∆M ∆M (b8) = 57.995 Da A. B. + 57.995 Da (CML) C. + 57.649 Da (CML)

27. + 71.987 Da (CEL) Sequence: 299-310 LKECCEKPLLEK Carbamidomethyl C (4), Carbamidomethyl C (5), CEL (7) ∆M ∆M (y6) = 71.987 Da A. B. C.